Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Alon Ben-Noon | Co-Founder, CEO & Director | 660k | -- | 1979 |
| Mr. Or Eisenberg | Chief Financial Officer | 382k | -- | 1981 |
| Ms. Hagit Binder | Chief Operation Officer | 232.62k | -- | 1978 |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer | 223.62k | -- | 1979 |
| Dr. Ferenc Tracik M.D. | Chief Medical Officer | 532k | -- | 1964 |
| Ms. Yael Barak | VP of Quality & Compliance | -- | -- | 1970 |
| Ms. Keren Pushett | Head of HR | -- | -- | -- |
| Mr. Eidan Loushi | C.R.A. | -- | -- | -- |
NeuroSense Therapeutics Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 18
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Corporate Governance
Upcoming Events
June 24, 2025 at 10:59 AM UTC - July 8, 2025 at 12:00 PM UTC
NeuroSense Therapeutics Ltd. Earnings Date
Recent Events
April 11, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
December 12, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission